Ha, ha. I will assume they just looked at raw numbers without factoring in the major earnings growth that will ensue because of Kyprolis approval. Why don't you explain how they came to their conclusion.
Dr, why you even bother to answer? Clearly he has no clue and saw ONXX ticker first time in his life. Well, he is going to learn that shorting biotech sometimes is not picnic.
I'd suggest him to short CLDX, even more fun....
I commented on this yesterday, but I am not sure why my post was deleted. Maybe it was because I included a link to the pomalidomide trial. In any event, bearofbleecker is on target with his analysis. In the long run pomalidomide shouldn't have an effect on Kyprolis sales for reason Bleecker posted. I will point out that pomalidomide is going for MM patients refractory to multiple treatment regimens including Velcade, so there could be some chance of it taking sales from Kyprolis in this population. However, Kyprolis will have a 6 months or more head start, and patients benefiting from it won't switch, and doctors using it will be more likely to use it for their other patients. In the long run, Kyprolis will be going after Velcade in front-line patients. Given its superior side-effect profile, I am guessing there could also be significant off-label usage of Kyprolis in this patient population. We will see in the next few quarters how it plays out, but I am not too concerned. Having said that, I am still looking to lighten up on ONXX a it to bank some profits as its big rise has made it too high of a percentage of my biotech portfolio for me to feel comfortable.